After the FDA approved Seagen’s (SGEN) Padcev plus Merck’s (MRK) Keytruda combo as a first-line treatment for mUC patients who are not eligible to cisplatin-based chemotherapy, BofA analyst Geoff Meacham said the approval "wasn’t unexpected," but argues that it should alleviate concerns on Pfizer’s (PFE) deal to acquire Seagen (SGEN). The firm believes "investors should breathe a sigh of relief" given that the news clears uncertainty around Padcev’s fate in first-line cis-ineligible mUC.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGEN:
- Seagen, Astellas announce FDA grants Padcev with Keytruda accelerated approval
- Seagen downgraded to Hold from Buy at Berenberg
- Seagen price target raised to $229 from $145 at TD Cowen
- Seagen price target raised to $229 from $152 at Truist
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley